Inhaled Agents

    Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysis

    Tricco AC, Strifler L, Veroniki AA, Yazdi F, Khan PA, Scott A, Ng C, Antony J, Mrklas K, D'Souza J, Cardoso R, Straus SE. Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysis. BMJ Open. 2015;5(10):e009183. DOI: 10.1136/bmjopen-2015-009183.

     

    Altmetric:

     

    Bottom Line:

    • Many inhaled agents are available for chronic obstructive pulmonary disease (COPD), some are safer and more effective than others

    Impact:

    • Our results can be used by patients and physicians to tailor administration of these agents
    • Commissioned by the Ontario Drug Policy Research Network to inform the listing of these agents by the Ontario Public Drug Program
    Funding:

    Ontario Drug Policy Research Network (ODPRN), Ontario Ministry of Health and Long-Term Care (OMHLTC)


    Comparative Safety and effectiveness of long-acting muscarinic antagonists for chronic obstructive pulmonary disease (COPD): A rapid review and network meta-analysis

    Tricco AC, Strifler L, Yazdi F, Khan P, Ng C, Antony J, Mrklas K, Scott A, D’Souza J, Cardoso R. Comparative safety and effectiveness of long-acting muscarinic antagonists for chronic obstructive pulmonary disease (COPD): A rapid review and network meta-analysis. Technical Report 2014.

     

    Bottom Line:

    • The results of a network meta-analysis (NMA) restricted to patients with moderate chronic obstructive pulmonary disease (COPD) found that tiotropium+formoterol had the highest probability of reducing the risk of exacerbations

    Impact:

    • Our results can be used by patients and physicians to tailor administration of these agents
    • Commissioned by the Ontario Drug Policy Research Network to inform the listing of these agents by the Ontario Public Drug Program

    Protocol:

    Additional Resources:

    Funding:

    Ontario Drug Policy Research Network (ODPRN), Ontario Ministry of Health and Long-Term Care (OMHLTC)


    Comparative safety and effectiveness of inhaled corticosteriods and beta-agonist for chronic asthma: A rapid review and network meta-analysis

    Tricco AC, Ashoor HM, Zarin W, Thomas S, Hamid J, Yazdi F, Lillie E, Kealey R, Ghassemi M, Loyman RJ. Comparative safety and effectiveness of inhaled corticosteroids and beta-agonists for chronic asthma: A rapid review and network meta-analysis. 2014.

     

    Bottom Line:

    • Fixed or adjustable dose combined inhalers with low dosage ICS+LABA, medium dosage ICS+LABA, or high dosage ICS+LABA had the greatest probability of decreasing the risk of moderate to severe exacerbations
    • There were no significant differences in risk of cardiovascular disease or cardiovascular related mortality across all treatment groups

    Impact:

    • Our results can be used by patients and physicians to tailor administration of these agents
    • Commissioned by the Ontario Drug Policy Research Network to inform the listing of these agents by the Ontario Public Drug Program

    Additional Resources:

    Funding:

    Ontario Drug Policy Research Network (ODPRN), Ontario Ministry of Health and Long-Term Care (OMHLTC)

     

    Category :

    Date : 29 Mar 2016